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The Differential Expression of Cide 
Family Members is Associated with 
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Clémence M. Canivet1,2, Pierre S. Leclere1, Jeanne Tran-Van-Nhieu3, Carmelo Luci  1, 
Béatrice Bailly-Maitre1, Xu Xu  4, Ann-Hwee Lee5, Kaori Minehira6, Rodolphe Anty1,2, 
Albert Tran1,2, Antonio Iannelli1,2 & Philippe Gual1
Improved understanding of the molecular mechanisms responsible for the progression from a “non-
pathogenic” steatotic state to Non-Alcoholic Steatohepatitis is an important clinical requirement. The 
cell death-inducing DFF45 like effector (CIDE) family members (A, B and FSP27) regulate hepatic lipid 
homeostasis by controlling lipid droplet growth and/or VLDL production. However, CIDE proteins, 
particularly FSP27, have a dual role in that they also regulate cell death. We here report that the 
hepatic expression of CIDEA and FSP27 (α/β) was similarly upregulated in a dietary mouse model of 
obesity-mediated hepatic steatosis. In contrast, CIDEA expression decreased, but FSP27-β expression 
strongly increased in a dietary mouse model of steatohepatitis. The inverse expression pattern of CIDEA 
and FSP27β was amplified with the increasing severity of the liver inflammation and injury. In obese 
patients, the hepatic CIDEC2 (human homologue of mouse FSP27β) expression strongly correlated 
with the NAFLD activity score and liver injury. The hepatic expression of CIDEA tended to increase 
with obesity, but decreased with NAFLD severity. In hepatic cell lines, the downregulation of FSP27β 
resulted in the fractionation of lipid droplets, whereas its overexpression decreased the expression 
of the anti-apoptotic BCL2 marker. This, in turn, sensitized cells to apoptosis in response to TNF α 
and saturated fatty acid. Considered together, our animal, human and in vitro studies indicate that 
differential expression of FSP27β/CIDEC2 and CIDEA is related to NAFLD progression and liver injury.
Non Alcoholic Fatty Liver Diseases (NAFLD) is a major public health concern with global prevalence ranging 
from 22% to 28%1. NAFLD is increasingly recognized as the most common chronic liver disease1. The spectrum 
of the hepatic diseases ranges from steatosis (fatty liver) to nonalcoholic steatohepatitis (NASH) (steatosis, inflam-
mation, liver injury) and subsequently to the activation of fibrogenic pathways, which correlates with a high risk 
of developing cirrhosis and hepatocellular carcinoma. Despite lifestyle changes and bariatric surgery for severe/
morbid obesity, the treatment of NAFLD (NASH) is still limited because of the lack of effective pharmacological 
treatment as well as lack of effective and practical diagnostic tools. NAFLD is associated with obesity and met-
abolic syndrome and the presence of type 2 diabetes mellitus can increase the risk of liver diseases2,3. Inversely, 
NAFLD is also a risk factor for many metabolic diseases, including type 2 diabetes4 and cardiovascular disease5.
The mechanisms underlying the transition from steatosis to NASH are multifactorial and not fully elucidated. 
The hepatocyte accumulation of triglycerides in lipid droplets is a protective mechanism that buffers free fatty 
acids and prevents lipotoxicity6. However, this protective mechanism can be overwhelmed. To illustrate this, it has 
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been reported that the inhibition of the triglyceride synthesis via the targeting of diacylglycerol acyltransferase 
2 (DGAT2) improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with NASH7. The 
vulnerable fatty hepatocytes generate danger signals including the release of alarmins and damage-associated 
molecular patterns as well as the enrichment of apoptotic bodies. This activation of sterile inflammation is 
involved in the initiation of a vicious cycle, where inflammation enhances hepatocyte death and vice-versa.
The cell death-inducing DFF45 like effector (CIDE) protein family, including CIDEA, CIDEB and CIDEC/
fat-specific protein 27 (FSP27), are lipid droplet-associated proteins. Since these proteins regulate lipid droplet 
synthesis and hepatic lipid homeostasis, they could be key players in the control of NAFLD progression8. The 
CIDEA is a short-lived protein that is mainly controlled by the sterol regulatory element binding protein-1c 
(SREBP-1c; master transcription factor regulated de novo lipogenesis) and shows increased expression in the 
case of hepatic steatosis9,10. Its overexpression in mouse liver resulted in augmented hepatic lipid accumulation 
and the formation of large lipid droplets. In contrast, the hepatic knockdown of CIDEA in obese mice resulted in 
significantly reduced hepatic lipid accumulation and smaller lipid droplets10. CIDEB is highly and constitutively 
expressed in the liver and controls both insulin sensitivity and VLDL maturation11,12. CIDEC, also known as 
fat-specific protein 27 (FSP27) in mouse, is also highly expressed in fatty liver and knock-down of its expression 
in fatty liver tissue ameliorated hepatic steatosis13–17. Its overexpression in hepatic cells enhanced the triglyceride 
content of lipid droplets17. The two FSP27α and β isoforms of mouse FSP27 (corresponding to human CIDEC1 
and 2, respectively) are regulated by the peroxisome proliferator-activated receptor gamma (PPARγ)14–17 and 
Cyclic-AMP-responsive-element-binding protein H (CREBH)18,19. The CIDE protein family can also mediate cell 
death depending on their expression levels and cellular localization20–23.
The relative expression levels of the three CIDE members over the transition period from simple steatosis 
to NASH has not yet been investigated. Interestingly, it has recently been reported that the strong upregulation 
of FSP27/CIDEC, with no change to CIDEA and CIDEB expression levels, contributes to alcohol-induced liver 
damage19. We therefore evaluated the expression level of the three CIDE members in NASH development and 
liver injury in experimental mouse models and in a cohort of patients at various stages of NAFLD progression.
Results
Hepatic expression of CIDEA, FSP27α and β increased with obesity-induced hepatic steatosis. 
We first evaluated the hepatic expression levels of CIDEA, CIDEB and FSP27α and β in dietary mouse models 
of obesity and hepatic steatosis. After 33 weeks of high-fat diet (HFD), the wild-type C57BL/6 (Wt) mice devel-
oped obesity (Supplementary Fig. 1A), severe hepatic steatosis (Supplementary Fig. 1B,C) and hepatic injury as 
assessed by ALT activity (Supplementary Fig. 1D). The hepatic expression levels of CIDEA and FSP27 α and β 
were robustly increased upon 33 weeks of HFD at both the mRNA (Fig. 1A) and protein (CIDEA and FSP27) 
(Fig. 1B) level. Hepatic expression of CIDEA, FSP27 α and β also correlated with hepatic steatosis and liver injury 
(Fig. 2A,B). These occurred at the same extent as evaluated by the FSP27 α /CIDEA and FSP27 β/CIDEA ratios 
which did not change with hepatic steatosis and did not correlate with liver injury (Figs 1C, 2C). The hepatic 
expression of FSP27α and β were similarly increased in obese mice (Fig. 1C: relative expression of FSP27β versus 
FSP27α). Even though it is robustly expressed in the liver (data not shown), hepatic expression of CIDEB did not 
change with obesity or hepatic steatosis (Fig. 1A). Steatosis and/or obesity were thus associated with the upregu-
lation of the hepatic expression of CIDEA, FSP27α and β.
Differential expression of CIDEA and FSP27β is related to the severity of the MCDD-mediated 
steatohepatitis. To subsequently investigate the behavior of the CIDECs in response to the progression 
and the severity of the NAFLD, we monitored their hepatic expression in wild-type mice fed a diet deficient in 
methionine and choline (MCDD) for 2 and 7 weeks. At 2 weeks, mice developed moderate hepatic steatosis with 
mild hepatic inflammation and liver injury (Supplementary Fig. 2). The long-lasting MCDD challenge (7 weeks) 
aggravated the liver complications with severe steatosis (from 50 ± 8% at 2 w to 81 ± 3% at 7 w, p = 0.0201), 
inflammation (from 9 ± 3 foci/10 fields at 2 w to 77 ± 7% at 7 w, p = 0.0024) and liver injury (ALT activity from 
51 ± 7 U/L at 2 w to 282 ± 42 U/L at 7 w, p = 0.0024) (Supplementary Fig. 2). Hepatic CIDEA decreased in concert 
with the severity of the NAFLD at both the mRNA and the protein level (Fig. 3A, D). Its hepatic expression nega-
tively correlated with hepatic inflammation (number of inflammatory foci) and liver injury (ALT activity) after 7 
weeks of MCDD (Fig. 4A). In contrast, the hepatic FSP27β was robustly augmented as NAFLD severity increased, 
from a 13-fold (±3) increase at 2 weeks to a 28-fold (±2) increase after 7 weeks of MCDD (Fig. 3B, D). Hepatic 
FSP27β also correlated with inflammation and liver injury after 7 weeks of MCDD (Fig. 4B). The increased 
FSP27 expression was mainly caused by the upregulation of FSP27β since FSP27α expression tended to decrease 
(Fig. 3B). This inverse regulation pattern for CIDEA and FSP27β expression was better illustrated by the FSP27β/
CIDEA ratio, with a 21-fold increase at 2 weeks versus a 48-fold increase at 7 weeks, p = 0.017 (Fig. 3C). This ratio 
also strongly correlated with hepatic inflammation and liver injury (Fig. 4C). The severity of the steatohepatitis 
was thus associated with an opposite expression of CIDEA and FSP27β.
Hepatic CIDEC2 correlated with the severity of the NAFLD in obese patients. To address the 
human relevance of our findings, we examined the relationship between hepatic CIDEA, CIDEB, CIDEC1 and 
CIDEC2 expression and the NAFLD progression from normal liver to steatosis and subsequent NASH in human 
liver biopsies from morbidly obese patients seeking for bariatric surgery. Patients were classified into 3 groups: 
without NAFLD, with hepatic steatosis (Steatosis) and with NASH (NASH) (assessed on the basis of three histo-
pathological features steatosis, lobular inflammation and hepatocellular ballooning; Table 1, Supplementary Fig. 3 
and Supplementary Methods). Liver mRNA levels of CIDEC2 were progressively upregulated with hepatic steato-
sis and subsequent NASH (Fig. 5A). This expression correlated with NAFLD features including hepatic steatosis, 
NASH and NAFLD activity score (NAS)(Fig. 5B). Hepatic CIDEC2 also correlated with hepatic injury as assessed 
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by ALT activity (Fig. 5C) and serum levels of keratin 18 (hepatocyte death marker) and caspase-generated keratin 
18 fragment (hepatocyte apoptotic marker)24,25 (Fig. 5C). As reported in the mouse model of steatohepatitis, the 
upregulation of CIDEC is mainly related to CIDEC2 expression since CIDEC1 is not altered (data not shown). In 
contrast, hepatic CIDEA tended to increase in obesity (lean versus obese patients without NAFLD) and then to 
decrease in NAFLD (Fig. 5A). This relationship was significantly amplified when the CIDEC2/CIDEA ratio was 
evaluated (with NAS: rs = 0.861, p < 0.001, n = 26)(Supplementary Fig. 3). Consistent with our animal results, the 
CIDEB expression was not modified with obesity and NAFLD (Fig. 5A) in human studies.
Down regulation of FSP27β resulted in a decreased lipid droplet size in mouse hepatocytes. 
Since FSP27β is localized on the surface of lipid droplets and is known to suppress lipolysis18, we therefore investi-
gated if altered FSP27β expression could affect hepatocyte lipid droplet synthesis. The down-regulation of FSP27β 
in AML12 hepatocytes (Fig. 6A), the main isoform expressed in hepatocyte (Fig. 6A), modified the size distribu-
tion of the lipid droplets in response to oleic acid (Fig. 6B, C). The number of small lipid droplets increased, while 
the number of large lipid droplets decreased. FSP27β expression could thus be involved in the development of 
hepatic macro-steatosis.
Overexpression of FSP27β sensitized hepatocytes to cell death in response to TNFα and pal-
mitic acid and led to decreased BCL2 expression. FSP27, in addition to regulating lipid droplet devel-
opment, could also mediate apoptosis in an expression-dependent fashion21,22,26. Furthermore, our human and 
experimental data strongly suggested that the expression level of FSP27β (mouse)/CIDEC2 (human) was associ-
ated with NAFLD progression and correlated with liver injury in NAFLD (Figs 2, 4 and 5). As TNFα was strongly 
upregulated in NASH liver, strongly correlated with ALT activity (HFD mice: rs = 0.666, p = 0.007, n = 15; 7 

















































































Figure 1. Hepatic expression of CIDEA, FSP27α and FSP27β increased with hepatic steatosis induced by 
HFD challenge. Wild-type mice fed a control diet (Ctrl D) (n = 7) or HFD (n = 7) for 33 weeks. (A, C) Hepatic 
expression of CIDEA, CIDEB, FSP27α and FSB27β was evaluated in Wt, Ctrl D and HFD mice at the mRNA 
level (7 mice/group). The gene expression was normalized to the mRNA levels of B2M or 36B4. Results are 
expressed relative to the expression level in controls (means ± SEM) and statistically analyzed using the Mann–
Whitney test. (B) Hepatic expression of CIDEA, FSP27 and HSP90 was evaluated in Wt, Ctrl D and HFD mice 
at the protein level (2–4 mice/group). *p < 0.05.
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evaluated the effect of the FSP27β overexpression on the sensitivity to cell death under basal conditions and in 
response to TNFα and TNFα with actinomycin D (Acti D). At baseline, the overexpression of FSP27β (Fig. 7A) 
caused minor increased cell death as evaluated by flow cytometry (Fig. 7B). This slight effect could be explained 
by the low percentage of transfected cells (20.48 ± 2.84% of GFP+ cells; n = 4). Interestingly, this cell death was 
associated with a decrease in anti-apoptotic BCL2 expression (Fig. 7A). Furthermore, these effects were further 
amplified in response to TNFα and TNFα with Acti D in HEPG2 cells overexpressing FSP27β, versus control 
HEPG2 hepatocytes (Fig. 7B). We then evaluated the effect of the FSP27β overexpression on HEPG2 viability in 
response to saturated fatty acid (palmitic acid), key player in hepatocyte lipotoxicity. Again, the cell viability was 
further decreased in response to palmitic acid in HEPG2 cells overexpressing FSP27β, versus control HEPG2 
hepatocytes (Fig. 7C). By regulating hepatic steatosis and liver injury, FSP27β thus plays a key role in the NAFLD 
progression to more severe complications, i.e., NASH.
Discussion
Here we report differential hepatic expression of CIDEA and FSP27β/CIDEC2 in response to increasing NAFLD 
severity. Hepatic FSP27β/CIDEC2 expression was not associated with obesity, but progressively increased with 
hepatic steatosis and subsequent steatohepatitis in mouse and human studies, respectively. In contrast, hepatic 
CIDEA increased with obesity but its hepatic expression tended to decrease with the severity of the steatohep-








































































Figure 2. Hepatic CIDEA, FSP27α and FSP27β correlated with hepatic steatosis and liver injury in HFD-
induced obese mice. Correlation between hepatic expression of CIDEA (A), FSP27α, FSB27β (B), FSP27α/
CIDEA ratio or FSP27β/CIDEA ratio (C) (fold) with hepatic steatosis (%) and ALT in Wt, Ctrl D and HFD mice 
(7 mice/group, 33 weeks of challenges) were analyzed using the Pearson’s correlation test.
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correlated with hepatic inflammation (number of inflammatory foci in mouse studies, and NASH and NAS in 
patients) and liver injury (ALT activity in mouse and human studies).
As previously demonstrated, the hepatic expression of CIDEA is increased in a mouse model of diet-induced 
obesity and hepatic steatosis9,10. This upregulation could be more closely associated with obesity than hepatic 
steatosis. Indeed, its hepatic expression tended to increase in obese patients without liver complications and 
metabolic syndrome, compared to lean patients. It has also been reported that the hepatic expression of CIDEA 
correlates with body mass index in obese patients31. CIDEA polymorphism has also been associated with obe-
sity in human32,33, although this could be more closely related to its role in adipose tissue. The role of CIDEA in 
hepatic triglyceride accumulation and lipid droplet formation has been clearly demonstrated and its targeting 
(overexpression and down regulation) regulates hepatic steatosis in obese mice10. In our cohort of obese patients 
and in a mouse model of steatohepatitis, the hepatic expression of CIDEA decreased with the severity of liver 
injury and steatohepatitis. However, it is important to emphasize that this is specific for CIDEA. Indeed, other 
important elements in the regulation of lipid droplet synthesis, such as PLIN5 and PNPLA2, are still upregulated 
in the fatty liver tissue of MCDD mice (after 7 weeks of MCDD: 2.3-fold increase for PLIN5, p = 0.0142; 3.13-fold 
increase for PNPLA2) and strongly correlate with hepatic steatosis in obese patients (PLIN5: rs = 0.698, p < 0.001, 
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Figure 3. Hepatic expression of FSP27β strongly increased with the severity of NAFLD whereas CIDEA 
expression decreased. Wild-type mice fed a control diet (Ctrl D) (n = 4) or MCDD (n = 6) for 2 and 7 weeks. 
(A, B, C) Hepatic expression of CIDEA, CIDEB, FSP27α and FSP27β was evaluated in Wt, Ctrl D and MCDD 
mice at the mRNA level (4–6 mice/group). The gene expression was normalized to the mRNA levels of B2M or 
36B4. Results are expressed relative to the expression level in controls (means ± SEM) and statistically analyzed 
using the Mann–Whitney test. (D) Hepatic expression of CIDEA, FSP27 and HSP90 was evaluated in Wt, Ctrl 
D and MCDD mice at the protein level (2–5 mice/group). *, versus Ctrl D, p < 0.05
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the down-regulation of SREBP-1c has been associated with the development of burned-out NASH34, the decrease 
in CIDEA could reflect the severity of NAFLD (NASH with fibrosis).
Similarly, the progressive upregulation of FSP27β/CIDEC2 with the progression of NAFLD could be a marker 
but also an important player. This gradual increase is more closely associated with FSP27β/CIDEC2 than FSP27α/
CIDEC1 in mouse and human studies. Xu et al., who first described the β isoform of FSP27 in fatty liver, also 
reported its upregulation in mouse models of diet-induced obesity and steatohepatitis and in human studies18. 
The “mild” upregulation of FSP27β could be related to hepatic steatosis as we and other groups have previously 
reported (Fig. 1 and13–17). Furthermore, we have observed that its down-regulation in hepatic cells promoted 
the fractionation of lipid droplets in response to oleic acid. In accordance with this, it has been reported that the 
down-regulation of FSP27β in steatotic liver tissue resulted in reduced accumulation of hepatic triglycerides and 
lipid droplets17.
The strong upregulation of FSP27β/CIDEC2 could be more closely related to steatohepatitis and liver injury. 
Hepatic expression of FSP27β/CIDEC2 shows a strong correlation with liver injury as evaluated by ALT activity 
(in mouse and human studies) and a serum marker of hepatocyte apoptosis (in humans). With the increasing 
severity of the steatohepatitis, hepatic expression of FSP27β rises to a 28-fold (±2) increase in 7 weeks MCDD 
mice, versus a 13-fold (±3) increase in 2 weeks MCDD and HFD mice. We also observed that overexpression of 
FSP27β sensitized hepatocytes to cell death mediated by cytokine (TNFα) and saturated fatty acid (palmitic acid). 
Several groups have reported that FSP27 is a potent apoptotic inducer via the activation of the pro-apoptotic 
caspases, which trigger both the release of cytochrome c from mitochondria and DNA fragmentation20–23. 
This apoptotic role for FSP27 was found to require the CIDE-C domain. In line with this, overexpression of 













































Figure 4. Hepatic CIDEA and FSP27β negatively and positively correlated with steatohepatitis and liver injury 
in MCDD mice, respectively. Correlation between hepatic expression of CIDEA (A), FSP27β (B) or FSP27β/
CIDEA ratio (C) (fold) with hepatic steatosis (%) and ALT activity (U/L) in Wt, Ctrl D and MCDD mice (4–6 
mice/group, 7-week challenge) were analyzed using the Pearson’s correlation test.
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(Supplementary Fig. 4), while FSP27α expression tended to decrease with the severity of the steatohepatitis. 
Interestingly, the same domain of FSP27 also mediated its localization to lipid droplets and its interaction with 
CIDEA21,35. The inverse patterns of regulation for the hepatic expression of CIDEA (down-regulated) and FSP27β 
(up-regulated) is robustly amplified with the NAFLD progression (FSP27β/CIDEA ratio ranges from 1.6 ± 0.6 in 
simple steatosis (HFD mice) to 21 ± 2 in steatohepatitis (2 weeks MCDD mice) and 48 ± 7 with advanced steato-
hepatitis (7 weeks MCDD mice)). This opposing regulatory pattern could also modify the role of the C domain 
of FSP27β, which could be more involved in the alteration of lipid droplets or the initiation of the apoptotic pro-
gram, rather than binding with CIDEA.
Interestingly, the role of FSP27/CIDEC has recently been investigated in alcoholic steatohepatitis. Xu et al. 
have reported that the elevation of FSP27 (both isoforms with FSP27β 1000-fold higher than FSP27α) was likely 
to induce steatosis and liver injury in mouse model of chronic plus binge ethanol feeding. In this mouse model, 
the expression of CIDEA and CIDEB was not modified, hepatic FSP27 was strongly upregulated and the down 
regulation of FSP27 in hepatocytes prevented liver injury combined with the mitochondrial production of ROS. 
The authors also reported that hepatic expression of CIDEC mRNA increased more than 40-fold in samples from 
patients with alcoholic hepatitis and correlated with severity of the disease19. The authors further reported that 
the sustained FSP27 elevation in hepatocytes likely causes chronic liver injury and inflammation, and may subse-
quently induce fibrosis in a mouse model that combines chronic and acute-on chronic liver injury19.
Finally, we also report that the hepatic expression of CIDEB (at the mRNA level) is independent of obesity, as 
previously reported31,36, and also independent of hepatic steatosis and steahepatitits in mouse and human studies. 
While the level of gene expression was stable, CIDEB was the most highly expressed among the 3 members of the 
CIDE family in hepatocytes (2000x more than CIDEA and 400x more than FSP27/CIDEC in mice and humans) 
and could be an important player in the development of hepatic steatosis since it regulates the formation of 
triacylglycerol-enriched VLDL particles36.
In this current study, we demonstrated that the hepatic expressions of the members of the CIDE family are 
differentially regulated according to the development and the severity of NAFLD in mouse and human studies. 
The gradual elevation of FSP27β/CIDEC2 expression with the development of hepatic steatosis and subsequent 
steatohepatitis reinforces our interest in this protein as a potential therapeutic target. It would need to be targeted 
only when robustly upregulated, and in a hepatocyte-specific manner in order to maintain its beneficial role in 
the storage of lipids in adipocytes37.
Material and Methods
Human samples. In this study, human samples (blood, liver biopsy) were from twenty-eight morbidly obese 
patients and five lean subjects. All information relative to the patients are described in Supplementary Methods, 
Table 1 and Ethics approval section.
Mice. Male mice were used in all experiments described in Supplementary Methods. All animal experiments 
were approved by the CIEPAL and Use committee.
Real-time quantitative PCR analysis has been performed as previously described38,39 and described in the 
Supplementary Methods.
Immunoblotting. Cells or frozen tissues were solubilized in lysis buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 
10 mM EDTA, 150 mM NaF, 2 mM sodium orthovanadate, 10 mM pyrophosphate, proteases inhibitors cocktail, 
without 
NAFLD with steatosis with NASH p
n 5 14 9
Age (years) 39.4 ± 5.9 37.4 ± 2.4 45.8 ± 3.6 0.186
Sex (F/M) 4/1 14/0 4/5 0.005
BMI (kg/m²) 43.4 ± 0.7 44.1 ± 1.4 43.3 ± 1.8 0.851
ALT (IU/L) 18.20 ± 4.48 26.47 ± 2.95 81.44 ± 26.19*,# <0.001
Insulin level (mIU/L) 7.00 ± 1.10 15.46 ± 3.21 28.67 ± 4.56*,# 0.003
Glucose level (mmol/L) 4.88 ± 0.14 5.44 ± 0.13* 6.70 ± 0.72* 0.014
HOMA-IR 1.52 ± 0.24 3.77 ± 0.80* 8.51 ± 1.36*,# 0.001
HbA1c (%) 5.34 ± 0.22 5.62 ± 0.12 6.40 ± 0.38*,# 0.028
Triglycerides (mmol/L) 1.05 ± 0.15 1.41 ± 0.17 3.42 ± 1.07*,# 0.007
HDL cholesterol (mmol/L) 1.53 ± 0.18 1.52 ± 0.10 1.07 ± 0.37*,# 0.006
NAFLD Activity Score (n) 0(5) 1(4)/2(4)/3(6) 5(9)
Grade of steatosis (n) 0(5) 1(4)/2(4)/3(6) 3(9)
Lobular inflammation (n) 0(5) 0(14) 1(9)
Hepatocellular ballooning (n) 0(5) 0(14) 1(9)
Table 1. Characteristics of 28 morbidly obese patients. Without NAFLD: patients with normal liver histology; 
Steatosis: patients with steatosis; NASH: patients with severe steatosis and NASH. Data are expressed as 
mean ± SEM and compared using the non parametric Kruskal-Wallis test (column p) and Mann Whitney test 
(*, #) for quantitative values and or Khi-deux test for qualitative values. *p < 0.05 compared with “Without 
NAFLD”. #p < 0.05 compared with “Steatosis”.
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and 1% Triton X-100) for 45 min at 4 °C. Lysates were cleared (14 000 rpm, 15 min). Proteins were quantified 
(BCA Protein assay kit, 23225 Thermo Fisher Scientific Inc.), separated by SDS-PAGE and immunoblotted as 
previously described38. The proteins were probed with anti-CIDEA (NBP1-76950, Novus Biologicals), anti-FSP27 




































































































Figure 5. Hepatic CIDEC2 expression progressively increased with steatosis and NASH in obese patients. (A) 
Liver CIDEA, CIDEB and CIDEC2 mRNA expression levels were analyzed by real-time quantitative PCR in 
lean patients (n = 5), in morbidly obese patients without NAFLD (n = 5), with hepatic steatosis (n = 14) and 
with NASH (n = 9). The gene expression values were normalized to RPLP0 mRNA levels. Results are expressed 
relative to the expression level in controls (means ± SEM) and statistically analyzed using the Mann–Whitney 
test. (B, C) Correlation between hepatic CIDEC2 expression (fold) with hepatic steatosis (%), ALT, NASH and 
NAFLD activity score (NAS), serum markers of hepatocyte apoptosis (caspases-generated keratin 18 fragment) 
and hepatocyte death (keratin 18) in 25–28 obese patients were analyzed using the Pearson’s correlation test.
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Cellular models and treatments. Down regulation of FSP27. Down regulation of FSP27 was achieved 
using ON-TARGET plus SMART pool technologies (L-040997, Mouse FSP27, NM_178373 or non-targeting 
siRNA as a control, Darmacon, CO) and Lipofectamine RNAiMAX technologies (MSS236551, Mouse FSP27 Life 
Technologies) in AML-12 hepatocytes (ATCC, CRL-2254). Following a 24-hour transfection, oleic acid (0.5 mM) 
was applied to cells for 16 hours. Cells were then rinsed twice with PBS and fixed with 4% formaldehyde solution. 
Lipid droplets were stained by Oil-Red O solution for 5 min. Microscope slides were prepared (x60 magnification) 
for lipid droplet quantification. The area of the lipid droplets was quantified (in pixels squared) and normalized 
by the number of nuclei on the slides.
Overexpression of FSP27β. HEPG2 cells (ATCC HB-8065) were transfected with pCMV-HA FSP27β or 
the empty plasmid (provided by Drs Xu Xu and Ann-Hwee Lee18) using a Jet PEI-hepatocyte mix assay 
(102-05NOzyme). After 48 h, cells were treated with TNFα (20 ng/ml), actinomycin D (0.1 µg/ml) with TNFα 
(20 ng/ml) or palmitic acid (1 mM) for 16 h. Gene expression, cell viability and cell death were then evaluated as 
indicated.
MTT assay. The assay is dependent on the ability of viable cells to metabolize a water-soluble tetrazolium 
salt into a water-insoluble formazan product. Following the indicated treatments, cells were incubated for 2 h 
with 0.5 mg/mL MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) in serum-free medium 
(DMEM). After removing the supernatant, DMSO was added to completely dissolve the formazan product. 
Aliquots of the resulting solutions were transferred to 96-well plates and the absorbance was recorded at 550 nm 
using the microplate spectrophotometer system (ELX800, Bio-TEK instruments). Results are presented as a per-
centage of the control values.
Cell death. Flow cytometry was used to evaluate cell death following double staining with annexin-V-PE and 
7-AAD according to the manufacturer’s instructions (Annexin V-PE apoptosis detection kit I, BD Biosciences, 
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Figure 6. Down regulation of FSP27β resulted in the fractionation of lipid droplets in AML12 hepatocytes. 
AML12 hepatocytes after control (siCtrl) or FSP27 silencing (si FSP27) were stimulated with oleic acid (0.5 mM) 
for 16 h (n = 3). (A) FSP27α and FSP27β mRNA expression levels were analyzed by real-time quantitative PCR. 
The gene expression was normalized to RPLP0 mRNA levels. (B,C) Lipid droplets were stained by Oil-Red O 
solution for 5 min. (B) Representative pictures are shown. (C) Lipid droplet areas were quantified (in pixels 
squared) and normalized according to the number of nuclei on the slides. Results are expressed relative to the 
control (siCtrl) as means ± SEM. Data were statistically analyzed using the Student’s t-test. *, versus siCtrl, 
p < 0.05.
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Statistical analysis. Statistical significance between two human or mouse study groups was determined 
using the nonparametric Mann–Whitney test. Data from cell lines were statistically analyzed using the Student 
t-test. Pearson’s correlation test has been used for the correlative analysis. Significance has been considered for 
P < 0.05.
Ethics approval. All subjects gave their informed written consent to participate in this study in accord-
ance with French legislation regarding Ethics and Human Research (Huriet-Serusclat law). The “Comité 
Consultatif de Protection des Personnes dans la Recherche Biomédicale de Nice” approved the study (07/04:2003, 
N° 03.017). The guidelines of laboratory animal care were followed. The local CIEPAL committee (Comité 
Institutionel d’Ethique Pour l’Animal de Laboratoire, national agrement n° 28) has approved the animal exper-
iments (NCE/2013-108, APAFIS#51 00–20 15121 1 10477413 v6). (Authorization of the C3M animal facility: 
B06-088-20).
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